Skip to content
CAR-based cellular therapy for refractory systemic lupus erythematosus: an overlap-controlled systematic review
§Regimen workspace

Where a regimen's kidney risks overlap

Assemble the agents in a regimen once, then read them two ways — the compounded risks where more than one agent hits the same kidney-injury signature, or a side-by-side comparison of their profiles. Built from the atlas's citation-grounded profiles.

Loading…
Data-viz lensSee the documented onco-onco synergy pairsThe 9 documented anti-cancer combinations whose kidney risk compounds beyond either agent alone, mapped as a network — the hubs that recur across regimens and the phenotype that dominates the synergies.

This is an educational overlap view derived from each agent's documented injury signatures, not a validated interaction model — it does not account for dose, sequence, patient factors, or synergy. Medical-education content only — not medical advice. Confirm against primary sources and current guidelines.